| Literature DB >> 21143928 |
Judith Farrés1, Albert Pujol, Mireia Coma, Jose Luis Ruiz, Jordi Naval, José Manuel Mas, Agustí Molins, Joan Fondevila, Patrick Aloy.
Abstract
BACKGROUND: The prevalence of type 2 diabetes is increasing worldwide, accounting for 85-95% of all diagnosed cases of diabetes. Clinical trials provide evidence of benefits of low-carbohydrate ketogenic diets in terms of clinical outcomes on type 2 diabetes patients. However, the molecular events responsible for these improvements still remain unclear in spite of the high amount of knowledge on the primary mechanisms of both the diabetes and the metabolic state of ketosis. Molecular network analysis of conditions, diseases and treatments might provide new insights and help build a better understanding of clinical, metabolic and molecular relationships among physiological conditions. Accordingly, our aim is to reveal such a relationship between a ketogenic diet and type 2 diabetes through systems biology approaches.Entities:
Year: 2010 PMID: 21143928 PMCID: PMC3009973 DOI: 10.1186/1743-7075-7-88
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Figure 1Ketogenic diet map and type 2 diabetes. A) Ketogenic-diet map by axPathNavigator™. Spheres represent proteins, lines are relationships between proteins and green triangles indicate proteins which are drug target. Seed proteins are colored in dark green. B) Diabetes clusters on 2D projection of ketogenic-diet map obtained through MDS transformation. The underling layer represents the ketogenic-diet map, the color grading of the image gives us an idea of the protein density, from black, no protein, until yellow areas of high protein density, see adjunct scale left (protein/pixel2). The overlaying image shows the location and density of the diabetes cluster on the ketogenic-diet map. Again, the color grading of the image gives us an idea of the protein density in this case from blue (low protein density) to dark red (high protein density), see adjunct scale right (protein/pixel2).
Figure 2Probability Density Function of Hausdorff distances. The Hausdorff distance between any pair of physiological conditions is calculated as the average number of jumps between each protein contained in the first physiological condition against the closest proteins in the second physiological condition and vice versa. A) Probability Density Function of Hausdorff distances for any pair of physiological conditions described in ax_SafetyDB. This distribution shows the relation between all physiological conditions contained in ax_SafetyDB. It comprises a total of 12,882 comparisons that give a normal distribution with an average distance of 2.3 jumps and a standard deviation of 0.5 jumps. As can be seen in the distribution 95% of the measures are greater than 1.5 jumps. B) Probability Density Function of Hausdorff distances for all physiological conditions contained in ax_SafetyDB to the ketogenic pathways (path 71 and 72). It comprises a total of 228 comparisons. As can be seen in the distribution 95% of the measures are greater than 2.3 jumps.
Relationship at metabolic pathway level between the ketogenic-diet map and type 2 diabetes
| Ketogenic-diet map | Pathophysiological pathways of Type 2 Diabetes | |
|---|---|---|
| % effector proteins present in ketogenic-diet map | 23% (7/30) | 56% (13/23) |
| Fatty acid metabolism (KEGG: HSA00071) | 2.3 (0.95) | 2.5 (0.85) |
| Synthesis and degradation of ketone bodies (KEGG: HSA00072) | 2.3 (0.95) | 2.5 (0.85) |
Values in brackets report the significance of the distance value. It has been estimated from the distribution of the Hausdorff distances of all pathophysiological conditions contained in ax_SafetyDB to pathways (path 71 and 72). The same principles as the ones described in figure 2 have been applied.
Direct relationships (1 jump) between seed proteins of ketogenic-diet map and type 2 diabetes effector proteins.
| Physiologic Pathway | Type 2 Diabetes Effector Protein (Protein Name) | |
|---|---|---|
| Insufficient insulin production | Somatotropin | GH1 |
| Solute carrier family 2, facilitated glucose transporter member 4 (GLUT4) | SLC2A4 | |
| E3 ubiquitin-protein ligase CBL (CBL) | CBL | |
| Protein kinase C alpha type (PRKCA) | PRKCA | |
| Insulin resistance | Nuclear factor NF-kappa-B p105 subunit (NFKβ) | NFKB1 |
| Insulin receptor substrate 1 (IRS-1) | IRS1 | |
| Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1-α) | PPARGC1A | |
| Protein kinase Akt-3 (PKBγ) | AKT3 | |
Figure 3Clusters of the different type 2 diabetes motifs on a 2D projection of ketogenic-diet map. The underlying image represents the ketogenic-diet map obtained through MDS transformation. The color grading of the image gives us an idea of the protein density, from black, no protein, until yellow areas of high protein density. Overlaying this image the localization of the protein clusters for the different type 2 diabetes motifs is presented. The color grading of images gives us an idea of the protein density from dark red (high-density proteins) to blue (low-density of proteins) (protein/pixel2).
Figure 4Protein relationship between effector proteins involved in the insufficient insulin production motive of diabetes and the key pathways of the ketogenic diet. Two complementary hypothesis of functional relationship between the molecules involved in both physiological processes have evolved: a) Elements of lipid metabolism may facilitate proper cellular localization of glucose transporter and recycling and b) Ketone bodies can alleviate certain inflammatory processes by blocking specific cytokines.